ABCL

AbCellera Biologics Inc. Common Shares

$12.37

Current Price

All

AI analysis

Read what the AI thinks of AbCellera Biologics Inc. Common Shares in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

-$0.54

P/E

—

Data as of Oct 8

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Expected EPS: -$0.17

Nov 9

Posts

No posts about ABCL yet.

About AbCellera Biologics Inc. Common Shares

AbCellera is a Canadian biotech company that searches for antibody drugs, which are proteins the body uses to fight disease. It uses its technology platform to find antibody candidates for partners, who pay fees and milestone payments, and it is building its own drug pipeline. Revenue is small and uneven because it depends on partner deals and project timing.